Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer

Abstract Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the...

Full description

Saved in:
Bibliographic Details
Published in:European journal of obstetrics & gynecology and reproductive biology 2017-03, Vol.210, p.355-359
Main Authors: Saijo, Masayuki, Nakamura, Keiichiro, Masuyama, Hisashi, Ida, Naoyuki, Haruma, Tomoko, Kusumoto, Tomoyuki, Seki, Noriko, Hiramatsu, Yuji
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinoma, Endometrioid - diagnosis
Carcinoma, Endometrioid - mortality
Carcinoma, Endometrioid - pathology
Endometrial cancer
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Female
Glasgow prognostic score
Humans
Japan - epidemiology
Middle Aged
Obstetrics and Gynecology
Poor prognosis
Prognosis
Retrospective Studies
Severity of Illness Index
Uterus - pathology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). Study design Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann–Whitney U test. PFS and OS were analyzed using the Kaplan–Meier method. Cox’s proportional hazard regression was used for univariate and multivariate analyses. Results Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan–Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0 + 1) (PFS: P < 0.001; OS; P < 0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P < 0.001) and survival (P < 0.001) for all cases of EC. Conclusion GPS can be useful as an indicator of poor prognosis in patients with EC.
ISSN:0301-2115
1872-7654
DOI:10.1016/j.ejogrb.2017.01.024